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We have recently reported the creation of the first immortal-
ized cell line derived from human dermal microvascular en-
dothelial cells (HMEC-l ). In preliminary studies this line 
was found to closely resemble microvascular endothelial cells 
in regard to many phenotypic characteristics . Because two 
key functional features of endothelial cells are their ability to 
bind to peripheral blood leukocytes and extracellular matrix 
proteins via cell adhesion molecules, we have now character-
ized HMEC-l in terms of expression and regulation of cell 
adhesion molecules of the integrin, immunoglobulin gene 
superfamily, and selectin families. HMEC-1 can either con-
stitutively express or can be induced to express key integrins, 
including a-l, -2, -3, -4, -5, -6, and -V, as well asp-1, -3, -4, 
and -5. They also express or are capable of expressing immu-
E ndothelial cells have become recognized as critical cells in a variety of basic physiologic and pathophysiologic processes, including inflammation, leukocyte traffick-ing, wound healing, angiogenesis, and tumor metastasis [1-11]. We and others have shown that important bio-
logic and functional differences exist between endothelial cells de-
rived from large versus small vessels [5.12-16]. These differences 
include growth characteristics [13.17,18]. tube-forming ability 
[5,19], prostaglandin secretory profile [12], expression and regula-
tion of cell adhesion molecules, and the ability to express leukocyte-
homing molecules [14,20-22].t Unfortunately, studies of human 
dermal microvascular endothelial cells (HDMECs) have been lim-
ited by their availability, because their isolation, purification. and 
serial propagation has proven to be difficult, time-consuming, and 
expensive. 
In an attempt to overcome these drawbacks of working with 
HDMECs. we have created the first immortalized human micro-
vascular endothelial cell line (HMEC-l) derived from human skin 
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no globulin gene superfamily molecules, such as intercellular 
adhesion molecule-l and vascular cell adhesion molecule-1, 
and a member of the selectin family, E-selectin. A number of 
important cell adhesion molecules that are either constitu-
t~vely expressed or that must be induced are regulated in a 
tlme- and dose-dependent fashion by selected cytokines. Ex-
periments comparing the phenotypic characteristics of 
HMEC-1 with human dermal microvascular endothelial 
cells or human umbilical vein endothelial cells reveal 
HMEC-1 to have features of both small- and large-vessel 
endothelial cells. Key words: cell adhesion molecules/integrins/ 
human dermal microvascular endothelial eel/line.] Invest Dermatol 
102:833-837, 1994 
and repor~ed on preliminary studies of its biologic characteristics 
[23] . In thls.study, we have thoroughly characterized the expression 
and regulatIOn of relevant cell adhesion molecules on HMEC-l as 
well as the functional characteristics of these cell-adhesion mole-
cules as defined by matrix-protein binding and T-cell binding. We 
have also performed direct comparisons with HDMECs and with 
human um~ilical vein endothelial cells (HUVECs). the most com-
monly studied large-vessel endothelial cell. Our studies demon-
strate that HMEC-1 possesses features of both HDMECs and 
HUVECs. 
MATERIALS AND METHODS 
Isolation and Culture of Human Dermal Microvascular Endothelial 
Cells (HDMECs) HDMECs were isolated from human neonatal fore-
skin~ as describe.d previously [5]. Culture medium was endothelial basal 
medlUm (Clonencs. Santa Ana. CAl with 30% normal human serum (Irvine 
SCientific. Santa Ana. CAl. 2 mM glutamine. 5 X 1O~' M dibutyryl cyclic 
AMP (Sigma. St. Louis. MO). 1 J.lg/ ml hydrocortisone acetate (Sigma). 
1 ng/ml epidermal growth factor (Clonetics). and 100 U/ml penicillin. 
10? ~ /ml streptomycin. 10 J.lg/ml ciprofloxacillin. and 250 J.lg/ml ampho-
tCrlcm B (Sigma). The resulting cell culrures were consistently 100% purc as 
a~sessed by morphologic and immunologic criteria. The cells could be con-
tmuously passaged up to 12 times and undergo at least 20 population dou-
blings. All cells were used at passages 2 to 8. 
Culture of the Endothelial Cell Line HMEC-l The HMEC-1 line 
was esta~lished as pre~iously reported [23] and passaged continuously in 
endothelial basal medlUm (Clonetics). supplemented with 10% normal 
human se.rum (Irvine Scientific). as well as with the additives noted above. 
Isolation and Culture of HUVECs HUVECs were isolated and pas-
sage? by a previously described technique [17]. HUVECs were grown in 
medlUm 199 (Irvine Scientific) with 20% fetal bovine serum (Gibco. Grand 
Island. NY). 50 J.lg/ml heparin (Sigma). 50 J.lg/ml endothelial cell growth 
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supplement (ECGS) (Collaborative Biomedical Products, Bedford, MA), 
2 mM glutamine (Sigma), and 100 U/ml penicillin, lOOllg/ml streptomy-
cin, and 2s0llg/ml amphotericin B (Sigma). HUVECs in passages 2 to 8 
were used for the parallel studies. 
Antibodies Monoclonal antibodies (MoAbs) to CD6 (clone SPV-L14, 
mouse immunoglobulin [lg]G 1), CD26 (clone B1.19.2, mouse IgG2a), and 
CD31 (clone s.6E, mouse IgGl) were obtained as purified antibodies 
(AMAC, Inc., Westbrook, ME). MoAbs to CD9 were obtained as tissue 
culture supernatants and ascites (clone FMC8, mouse IgG2a; Accurate 
Chemical, Westbury, NY) and as purified antibody (clone ALB6, mouse 
IgG1; AMAC). Hybridomas secreting MoAb to major histocompatabiliry 
complex (MHC) class I (W6/32, mouse IgG2a) and class II (L243, mouse 
IgG2a) were obtained from American Type Cell Culture (Rockville, MD) 
and used as tissue culture supernatants or diluted ascites. Purified MoAbs to 
CD 1 0 and Leu-8 (L-selectin) were obtained commercially from Becton-
Dickinson Immunocytometry System, Mountain View, CA. Purified 
MoAbs to intercellular adhesion molecule 1 (ICAM-l, clone 84HIO, mouse 
IgGl) and lymphocyte function antigen-3 (LFA-3) (clone TS2/9, mouse 
IgGl) were the generous gift of Dr. Stephen Shaw, National Institutes of 
Health. Purified MoAbs or ascites to CD44 (clone AIG3 and A3D8, mouse 
IgG2) were the generous gifts of Dr. Bart Haynes, Duke University, Dur-
ham, NC. Purified MoAb directed against CD36 (clone OKMs and OKM8, 
mouse IgGl) was the generous gift of Dr. Patricia Rao (R.W. Johnson 
Pharmaceutical Research Institute, Raritan, NJ). MoAbs RBA-84100-A 
(clone A-I0-33-1, mouse IgG1), RBA-84102A (clone H3-s/47, mouse 
IgG2a), and RBA-84103A (clone H4-7/33, mouse IgG) were obtained as 
tissue culture supernatants, with the exception ofRBA-84102A, which also 
used as diluted ascites (Accurate). MoAbs to C013 (clone My7, mouse IgG 1) 
and CD29 (P-1 chain) (clone 4B4, mouse IgG1) were obtained from Coulter 
(Hialeah, FL). MoAb to CD49a (a-l chain) was a generous gift of Dr. E. 
Wayner (University of Minnesota). Purified MoAbs to CD49b (a-2 chain) 
(clone PIE6, mouse IgGl), CD49c (a-3 chain) (clone P1Bs, mouse IgG1), 
C04ge (a-s chain) (clone PID6, mouse IgG3), and to P-4 (clone 3El, 
mouse IgG1) were obtained from Telios (San Diego, CAl. MoAbs to CD49d 
(a-4 chain) (clone HP2.1, mouse IgGl) and CD49f (a-6 chain) (clone 
GoH3, rat IgG2) were obtained from AMAC. Purified MoAbs to CDs6 
(NCAM) were bbtained from Becton-Dickinson Immunocytometry System 
(Leu 19) and from Biode'sign International (clone NKl-nbl-l, mouse IgG 1; 
Kennebunkport, ME). MoAb to CDsl (a-V chain) (clone 3F12, mouse 
IgG1) and clone B6H12 were the generous gift of Dr. E. Brown (Washing-
ton University). MoAb to CD61 (P-3 chain) (clone AP3, mouse IgGl) was 
the generous gift of Dr. P. Newman (Milwaukee Blood Institute). MoAb 
to CD71 (transferrin receptor) (clone B3/2s, mouse IgGl) was obtained 
from Hybritech Inc. (San Diego, CAl. MoAb to E-se!ectin (clone 7A9, 
mouse IgGl) was the generous gift of Dr. W. Newman (Otsuka American 
Pharmaceuticals). MoAbs to VCAM-l (clone P3C4, mouse IgGl) and to 
a-V /fJ-s (clone PIF6, mouse IgG) were the generous gifts of Dr. E. Wayner 
(University of Minnesota). MoAb to endoglin (clone 44G4, mouse IgG) was 
a generous gift of Dr. M. Letarte (Hospital for Sick Children, Toronto, 
Canada). Polyclonal antibodies to Factor XIII a-subunit and Factor Xlll 
s-subunit (rabbit IgG) were obtained from Calbiochem (San Diego, CAl. 
Flow Cytometry Cells were analyzed for expression of cell-surface mol-
ecules using flow cytometry as previously described [20,21]. 
Enzyme-Linked Immunosorbent Assay (ELISA) Endothelial cells 
were plated into 96-well flat-bottomed tissue-culture plates 24-28 h in 
advance. Cells were stimulated with interleukin (IL)-1a or tumor necrosis 
factor (TNF)-a 100 U/ml from 0-72 h or with varying doses for 4 h at 
37°C, and then analyzed for the expression of selected cell-surface mole-
cules using ELISA as previously described [21]. All determinations were 
done in quadruplicate, and results were expressed as mean ± SD. 
Cell-Matrix Adherence Assay Fibronectin (20 Ilg/ml) vitronectin 
(20 Ilg/ml), lamiain (20 Ilg/ml), aad collagen I (1 Ilg/mI) (Chemicon, 
Temecula, CAl were dissolved in bicarbonate coating buffer and 48-well 
tissue-culture plates were coated by adding 100 III of matrix proteins to each 
well and then incubated overnight in the refrigerator. Coating solution was 
discarded, wells were blocked with blocking buffer (1 % heat deaatured 
bovine serum albumin [BSA) in Hank's balanced salt solution [HBSS] with 
0.1 % azide) for 1 h and washed with HBSS. HDMECs or HMEC-l were 
labeled overnight with 100 IlCi 51Cr in 15 ml culture medium for 4 X 106 
cells. Cells were thea removed with trypsin/ethylenediamine tetraacetic 
acid (EDTA) and washed with HBSS. Cells (2 X 104) were added to each 
well precoated with matrix proteins in 200 III HBSS with 1 % BSA and 
incubated at 37"C for 2 h. In blocking studies, peptide RGD (100 Ilg/ml) or 
RGE (100 Ilg/ml) (Telios) were pre-incubated with the matrix proteins for 
15 min at room temperature. and then cells were added to the wells without 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
Table I. Expression of Integrins 
Antigen/Epitope CD HDMECs HMEC-1 HUVECs 
a- I CD49a +++0 ++ 
a-2 CD49b ++++ +++ ++++ 
a-3 C049c ++++ ++++ +++ 
a-4 CD49d + ++ 
a-s CD4ge +++ ++++ +++ 
a-6 CD49f +++ ++++ ++ 
a-v CDs1 ++++ +++ ++++ 
P-1 CD29 ++++ ++++ ++++ 
fJ-3 CD61 ++ ++ +++ 
P-4 ++ ++++ + 
a-v/p-s + + + 
B6H12 ++++ ++++ +++ 
• -. mean channel fluorescence (MCF) <2 X MCF of control-stained cells; +. 
MCF 2-4 X control; ++. MCF 5-10 X control; +++, MCF 10-20Xcontrol; 
++++. MCF > 20 X control. 
washing. Non-adherent cells were removed by gently washing three times 
with HBSS with BSA. Adherent cells were then solubilized with 1 % Tri-
ton-X and counted in a gamma counter. Experiments were performed in 
triplicate. Percent of adherent cells was calculated as follows: 
dh ' counts adherent - background counts 1000' Percent a eSlOn = - X 70. 
total counts added - background counts 
T-Cell Adhesion Assay Untransformed microvascular endothelial cells, 
HMEC-l, or HUVECs were plated on 48-well tissue-culture plates in 
advance and stimulated with TNF-a at doses ranging from 2.5 V/mI to 
500 U / ml for 6 h or at 100 V / mI from 4 to 48 h, or were left unstimulated. 
Peripheral T lymphocytes were isolated from volunteers using Immulan 
T-cell separation kit (Biotex Laboratories, Inc., Houston, TX) following the 
manufacturer's protocol. T cells were then labeled with 51Cr (1 mCi/l06 
cells X 1 h at 37°C). This procedure routiaely yields preparations ofT cells 
that are over 95% pure. The T cells were then layered onto monolayers of 
HDMECs or HMEC-1. After 30 min of incubation at 37"C, aon-adherent 
T cells were removed by washing three times with HBSS, aad adherent 
T cells were solubilized with 1 % Triton X and counted in a gamma counter. 
The percent ofT-ceil adhesion was calculated using the following formula: 
Percent binding -'-ac::.d-;-h_er_e_n_t_c_o_u"'n"'ts-;-........:b-;-a..:.ck-,g~r-'o:...:u:.::.n"'d-,c:..:o:...:u",n",t,,-s X 100%. 
total counts added - background counts 
Reagents Recombinant human IL-la and TNF-a were purchased from 
R&D systems (Minneapolis, MN). Phorbol myristate acetate (PMA) was 
obtained from Sigma. Fluorescein isothiocyanate (FITC)-col~ugated goat 
anti-mouse IgG was purchased from Caltag Laboratories (San Francisco, 
CAl· FITC-conjugated goat anti-rabbit IgG was obtained from Tago Inc. 
(Burlington, CAl. 
Statistics Statistical significance of data was calculated using the fWO-
sided Student t test. 
RESULTS 
Endothelial Cell Markers We have previously shown that 
HMEC- I resembles HDMECs morphologically, in tube-forming 
abi lity on matrigel, and uptake of acetylated low-density lipopro-
tein (LDL). Originally, HMEC-l expressed von Willebrand's fac-
tor (Factor VIII-related antigen) but with continued culture, this 
feature has been lost. Moreover, cell-surface expression of CD36, a 
marker for microvascular endothelial cells that was also originally 
expressed by HMEC-I, has been lost with continued passage of the 
cell line. The other features noted above remain unchanged. 
HMEC-I remains morphologically indistinguishable from 
HDMECs and HUVECs and has retained its ability to form tubes on 
matrigel and take up acetylated LDL, despite prolonged passaging. 
Cell-Adhesion Molecule Expression Integrins (Table I) We 
found that HMEC-I constitutively expressed all integrins that we 
tested for, including a-1, -2, -3, -4, -5, -6, and -V, as well as p-1, -3, 
-4, and aVpS. These characteristics were qualitatively identical 
with those of HDMECs but varied somewhat with those of 
HUVECs. HUVECs were found to lack a-I and -4 and also ex-
pressed much less P-4 than HMEC- l. 
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Table II. Expression of Ig Supergene Family Molecules· 
CD Antigen/Epitope HOMECs HMEC-l HUVECs 
CD31 ++++ ++++ ++++ 
CD36 TSP Receptor ++ 
CD 54 ICAM-l +++ ++++ ++ 
CD56 NCAM ++ 
CD58 LFA-3 +++ +++ +++ 
VCAM-l 
MHC Class I ++++ ++++ ++++ 
MHC Class II 
• Scale as in Table I. 
Ig Supergene Family (Table II) HMEC-l constitutively ex-
pressed platelet-endothelial cell adhesion molecule (CD31) , 
ICAM-l (CD54), LFA-3, and MHC class I but lacked CD36 
(thrombospondin receptor), NCAM, and MHC class II. These phe-
notypic characteristics were identical to those of HUVECs but dif-
fered from HDMECs, which expressed both CD36 and NCAM. 
Selectins Fluorescence-activated cell sorter (FACS) analysis and 
ELISA measurement of all three types of endothelial cells revealed 
that none of the cells constitutively expressed E-selectin, L-selectin, 
or P-selectin. 
Miscellaneous Cell-Surface Antigens (Table III) A number 
of other cell-surface antigens often associated with endothelial cells 
were assayed on HMEC-l and then compared with HDMECs and 
HUVECs. The results show that the endothelial cell markers EN4, 
H3-5/47, RBA-84100-A, and endoglin were expressed on all three 
rypes of cells, and PAL-E was expressed on both HMEC-l and 
HDMECs and was not evaluated on HUVECs. In addition, CDlO, 
a cell-surface endopeptidase that inactivates substance P, was heav-
ily expressed by HMEC-l and in lesser amounts by HUVECs, 
was absent on HDMECs. Factor XIII a-subunit and Factor XIII 
s-subunit were expressed by all three cell types. 
Regulation of Cell-Adhesion Molecule Expression by 
HMEC-l Because some cell-adhesion molecules expressed by 
large- and small-vessel endothelial cells are known to be upregu-
lated or induced by pro-inflammatory mediators, we examined 
HMEC-l for cell adhesion molecule modulation following stimu-
lation with selected cytokines or PMA. 
Table III. Expression of Miscellaneous Cell-Surface Antigens· 
CO Antigen/Epitope HOMECs HMEC-l HUVECs 
CD6 + + + 
CD9 ++++ ++++ ++++ 
CDlO +++ + 
CD13 +++ +++ +++ 
CD26 + ++ + 
CD44 ++ ++++ ++++ 
CD71 Transferrin +++ +++ +++ 
Receptor 
Endoglin +++ ++++ ++++ 
Leu-13 
Factor XIII, ++++ ++++ ++++ 
a-subunit 
Factor XIII, ++++ ++++ ++++ 
s-subunit 
EN4 ++++ ++++ ++++ 
PAL-E + +++ NO' 
H3-5/47 ++++ ++++ + 
RBA-84100-A + + + 
• Scale as in Table I. 
b NO, not done. 
CELL ADHESION MOLECULES ON HMEC-l 835 
Table IV. Integrin Expression on HMEC-l· 
FACScan Analysisb ELISA' 
Untreated PMA Untreated PMA 
0'-2 80 ±9 308 ± 8 0.101 ± 0.005 0.412 ± 0.04Y 
0'-3 341 ± 8 238 ± 8 0.248 ± 0.025 0.158 ± 0.020J 
0'-5 170 ± 7 175 ± 8 0.151 ± 0.014 0.161 ± 0.016 
0'-6 54± 7 31 ± 8 0.045 ± 0.006 0.021 ± 0.016' 
a-v 155 ± 7 271 ± 9 0.147 ± 0.019 0.365 ± 0.017J 
P-l 256 ± 7 235 ± 8 0.199 ± 0.006 0.216 ± 0.019 
P-3 43 ± 9 103 ± 9 0.045 ± 0.006 0.158 ± 0.005J 
P-4 46±8 13 ± 9 0.054 ± 0.004 0.019 ± 0.001 J 
• Cells were treated with PMA 100 ng/ ml for 72 h or left untreated and then 
analyzed by FACScan analysis or by ELISA. 
• Mean channel fluorescence. 
, Optical density, 450 nm. 
J p <O.Q1. 
'p <0.05. 
Regulation of Integrin Expression (Table IV) To see 
whether integrin expression on HMEC-l could be regulated, 
HMEC-l were stimulated with PMA (100 ng/ml) for 72 hand 
analyzed by FACS or ELISA. PMA stimulation caused marked in-
creases in the expression of some integrin chains and decreases in 
some; others were unaffected. Specifically by FACS analysis, the 
0'-2, a-V, and P-3 chains were increased by 285%, 74%, and 140%, 
respectively. 0'-3, 0'-6, and P-4 expression was decreased by 30% 
43%.' and 72%, respec.tiv.ely. 0'-5 and P-l were unchanged. ELISA 
studies revealed very Similar data, although the percentage increase 
or decrease was usually greater. 
At the fu.nctional level, a-Vis usually paired with P-3, and be-
ca.use bO.th 1I1tegnns showed substantial increases following PMA 
st1l11UlatlOn, w~ examlI~ed a-V regulation in more depth. In a dose-
respo.nse exper~ment WIt!: PMA at 72 h (Fig 1),0'-V showed signifi-
cant 1I1crease.s 111 expressIOn following 10-ng, 25-ng, and 100-ng 
doses. The differences between 25 ng and 100 ng were not signifi-
cant. 
Regulation of Ig Supergene Family Cell-Adhesion Mole-
cules on HMEC-l The regulation of cell-adhesion molecules 
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Figure 1. An ELISA experiment demonstrating that PMA upregulates a-V 
expression on HMEC-l in a dose-dependent manner. HMEC-1 were treated 
with PMA 10 ng/ml - 100 ng/ml for 72 h or left untreated, and cell-surface 
expression of a-V chain was measured by ELISA. Results represent the 
mean ± SO of four data points. p < O.~5; •• P < 0.01. 
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Figure 2. A bar graph comparing the induction ofVCAM-l expression by 
TNF-a or IL-l-cx. HMEC-l were stimulated with TNF-cx 100 U/ml or 
IL-l-cx 100 U/ml from 4 to 72 h or unstimulated, and then VCAM-l 
expression was detected with ELISA. TNF-cx dramatically induced 
VCAM-l expression, whereas IL-l-a slightly induced VCAM-l expression 
as compared to TNF-cx. Results represent the mean ± SD offour data points. 
p < 0.05; •• P < om. 
demonstrated previously that ICAM-l expression on HMEC-l 
could be upregulated by TNF-a or IL-la in a time- and dose-
dependent manner ([23] and unpublished observation). VCAM-l is 
a critical cell-adhesion molecule that is not constitutively expressed 
on endothelial cells but which can be induced by both TNF-a and 
IL-la on HU'lECs but only induced by TNF-a and not IL-la on 
HDMECs. As noted above, VCAM-l was absent on unstimulated 
HMEC-1. TNF-a (100 U/ml) stimulation of HMEC-l induced 
large amounts ofVCAM-l as early as 4 h that persisted for at least 
72 h (Fig 2). Because 4 h seemed to be at or near the peak of 
VCAM-l induction by TNF-a, we performed dose-response evalu-
ation at this timepoint. 
As little as 25 U/ml of TNF-a induced VCAM-l, and doses 
higher than 100 U/ml continued to induce even more VCAM-l 
(optical density 450 > 0.3). IL-la stimulation ofHMEC-l resulted 
in relatively little expression ofVCAM-1. In a time-course study, 
the expression ofVCAM-l induced by IL-la (100 U Iml) was only 
18% of that induced by TNF-a (100 U Iml) at 4 h (Fig 2). However, 
in dose-response studies, large doses oEIL-la, 500 U - 2500 U, did 
induce stepwise increases in VCAM-l expression (optical density 
450,0.07 -0.12). These increases were much less than noted with 
the same doses of TNF-a. 
Regulation of Select ins on HMEC-l E-selectin is inducible on 
both macrovascular and microvascular endothelial cells by TNF-a 
and IL-la. Studies of HMEC-l showed that small amounts of 
E-selectin were inducible at 4 h by both TNF-a (100 U/ml) and 
IL-la (100 U Iml) (Fig 3), although TNF-a induced higher levels 
that persisted longer. In dose-response studies at 4 h, 25 U of 
TNF-a induced E-selectin but 500 U of IL-la were needed to 
induce significant increases. At extremely high doses, IL-la and 
TNF-a induced comparable levels of E-selectin. However, these 
levels were much lower compared with those on HDMECs or 
HUVECs with similar doses (data not shown). P-selectin was not 
induced by stimulation of HMEC-l with 1 f.1.m thrombin for 
10 min. 
Binding Characteristics ofHMEC-l Because endothelial cells 
are known to bind to peripheral blood leukocytes and also to extra-
cellular matrix, we examined HMEC-l for these functional capa-
bilities. 
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Figure 3. An ELISA experiment illustrating the induction of E-selectin 
expression. HMEC-l were treated with TNF-cx or IL-l-cx 100 U/ml for 
varying times, and cell-surface expression was measured. E-selectin expres-
sion was maximally detected at 4 h. Although TNF-cx appeared to be more 
effective in induction of E-selectin than IL-l-cx, the overall expression was 
low. Results represent the mean ± SD of four data points. p < 0.05; •• P < 
om. 
T-Cell HMEC-l Adhesion Assay HMEC-l were compared 
with HDMECs and HUVECs for their ability to bind T cells and 
for this binding to be modulated by TNF-a. Time-course and dose-
response experiments revealed that, although baseline binding of 
T cells to HMEC-l (28 .2%) was higher than to HDMECs (23.8%) 
or HUVECs (18 .7%), the respollSe to TNF-a (100 U) was qualita-
tively similar in all three cell types, with peak binding ranging from 
34.7% (HDMECs) to 38.9% (HUVECs). 
Endothelial Cell-Matrix Binding Assay To examine whether 
HMEC-l bind to extracellular matrix proteins as HDMECs do, 
HMEC-l or HDMECs were labeled with StCr and layered onto the 
matrix proteins. HMEC-l bound to the extracellular matrix pro-
teins fibronectin, vitronectin, laminin, and collagen I in a manner 
similar to HDMECs (Fig 4). However, some quantitative differ-
ences were found, especiaIly that a higher percentage of HDMECs 
bound to vitronectin than did HMEC-1. Moreover, whereas RGD 
but not RGE peptides could inhibit the binding of both HMEC-l 
and HDMECs to vitronectin, the inhibition of HDMEC binding 
was much greater. RGD or RGE did not result in inhibition 
of binding of either cell type to fibronectin, laminin, or colla-
gen 1. 
DISCUSSION 
Our previous limited characterization demonstrated that HMEC-l 
retained many of the characteristics of endothelial cells. To deter-
mine whether HMEC-l can be used effectively as a substitute for 
primary HDMECs in the elucidation of the role of microvascular 
endothelial cells in the pathophysiologic processes, HMEC-l were 
further characterized. The initial examination of HMEC-l for the 
presence of cell-surface molecules revealed that it expressed all the 
endothelial cell markers examined, such as EN4, PAL-E, H3/5 -47, 
and CD36, which have previously been identified to be present on 
HDMECs [24] . Moreover, early studies indicated morphologic 
similarity with HDMECs and that HMEC-l formed tubes on ma-
trigel, took up Ac-LDL, and expressed vWF. These characteristics 
have remained stable, with the exceptions of vWF and CD36. 
HMEC-1 no longer expresses either of them, although mRNA for 
vWF is still present (data not shown) . 
Our expanded studies of HMEC-l revealed that this endothelial 
cell line still retains nearly all of the characteristics of endothelial 
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Figure 4. A bar graph comparing the adhesion of endothelial cel ls to extra-
cellular matrix proteins. Both HOMECs and HMEC-1 bound to extracel lu-
lar matrix proteins fibronectin (FN), vitronectin (VN), laminin (LM), and 
collagen I (Coll I) but not to BSA. The adhesion ofHOMEC and HMEC-1 
to vitronectin was blocked by RGO peptide but not by RGE peptide. Results 
represent the mean ± so of three data points. p < 0.05; •• P < 0.01. 
cells. When HMEC-l was compared with large- (HUVEC) and 
small- (HDMEC) vessel endothelial cells in regard to cell-adhesion 
molecule expression, overall broad similarities were noted in the 
expression of integrins, Ig supergene family proteins, and selectins . 
However, some differences were noted. For example, HMEC-l 
resembles HUVECs in that it lacks expression ofCD36 and NCAM 
but does express CDIO. HDMECs do express CD36 and NCAM 
but not CDIO. Alternatively, HMEC-l is similar to HDMECs in 
that it expresses the integrins cd and a4 whereas HUVECs do not. 
Examination of HMEC-l for cell-adhesion molecule regulation 
revealed that unstimulated HMEC-l had a relatively high baseline 
expression ofICAM-l, as observed before [24]. ICAM-l expression 
could be further upregulated by IL-la or TNF-a in a time- and 
dose-dependent manner. HMEC-l did not constitutively express 
E-selectin, but IL-la and TNF-a did induce a small amount of 
E-selectin expression in a time- and dose-dependent fashion. How-
ever, the expression was rather transient, appearing only 4 - 6 h after 
treatment. The amount induced was not as impressive as seen with 
HDMECs, although it appeared that TNF-a may be more effective 
than IL-la in inducing E-selectin. VCAM-l was not present on 
unstimulated HMEC-l. TNF-a dramatically induced VCAM-l 
expression, with its peak at 4 h, it was maintained through 24 hand 
remained elevated at 72 h. VCAM-l expression was induced by as 
little as lOU /ml with TNF-a and increased significantly with 
increasing doses. Of note was that IL-la, which only minimally 
induces VCAM-l expression on HDMECs, readily induced 
VCAM-l expression on HMEC-l in a dose- and time-dependent 
manner, although it was not as dramatic as TNF-a. In addition, 
IL-4, which induces VCAM-l expression on HUVECs but fails to 
induce VCAM-l on HDMECs, also failed to induce VCAM-l ex-
pression on HMEC-l (data not shown) . 
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Taken together, these data provide further evidence that 
HMEC-l cells are similar to HDMECs but also have some features 
of HUVECs. As a cell line, it may be a useful substitute for the 
primary microvascular endothelial cells by allowing investigators to 
avoid the tedious isolation, purification, and growth of pure micro-
vascular endothelial cells, and to overcome the lot-to-lot variability 
and limited lifespan ofHDMECs. Moreover, these cells can be used 
to establish stable transfectants by transfecting the gene(s) of interest 
into the cell and then study the gene regulation in an endothelial 
cell context. 
In summaty, this immortalized human microvascular endothelial 
cell line should prove to be useful in the dissection of the role of the 
microvascular endothelial cells in a number of physiologic and 
pathophysiologic processes. 
This research was supported by NIH Grouts R01 AR39632 aud R01 AR41536. 
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